Is BDRX or BGMS more undervalued in 2026?

CirclFi compares Biodexa Pharmaceuticals plc (BDRX) and Bio Green Med Solution, Inc. (BGMS) using 13 institutional-grade valuation models. BDRX has a Quality of Company score of 1.7/10 while BGMS scores 5.1/10.

Which is a better buy — BDRX or BGMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BDRX and BGMS valuations compare?

BDRX at $3.36 and BGMS at $1.05 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BDRX vs BGMS Valuation Comparison 2026 — Intrinsic Value Analysis

BDRX

Biotechnology

Biodexa Pharmaceuticals plc

Quality

1.7

out of 10

Value Trap

—

Price

$3.36

Last close

Models

6/13

Active

BGMS

Biotechnology

Bio Green Med Solution, Inc.

Quality

5.1

out of 10

Value Trap

WARN

Price

$1.05

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	BDRX Fair Value	BDRX Upside	BGMS Fair Value	BGMS Upside
Bayesian DCF	Intrinsic	$0.89	-73.5%	$0.44	-57.9%
Earnings Power Value	Intrinsic	—	—	$0.98	+0.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.04	-7.9%	$0.39	-62.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BDRX vs BGMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BDRX vs BGMS — Which Stock Is More Undervalued?

BGMS scores higher with a 5.1/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Biodexa Pharmaceuticals plc (BDRX) and Bio Green Med Solution, Inc. (BGMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BDRX currently trades at $3.36 with a QOC of 1.7/10, while BGMS trades at $1.05 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).